BCRX

NASDAQ · Biotechnology

Biocryst Pharmaceuticals Inc

Mid-Cap Stocks Stocks Under $10 Biotech Stocks Healthcare Stocks

$9.38

+0.08 (+0.86%)

As of Aug 8, 10:08 PM ET ·

BCRX News3 articles

BioCryst Shares Slip on New HAE Drug Data, Focus Shifts to Cowen Conference

BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO and targets a late-2027 regulatory submission.

BioCryst Shares Slide on HAE Drug Data, Focus Shifts to Cowen Conference

BioCryst Pharmaceuticals shares fell nearly 3% in premarket trading following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO.

BioCryst Shares Slip on New Hereditary Angioedema Drug Data

BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company reaffirmed its 2026 revenue outlook and plans a Phase 3 filing by late 2027.